Latest Salix Pharmaceuticals (SLXP) Headlines R
Post# of 37
Posted On: 03/13/2014 2:02:01 PM
Latest Salix Pharmaceuticals (SLXP) Headlines
Roche Collaborates with Bayer - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 12, 4:05PM CDT
Roche's Ventana Medical Systems, Inc. has entered into a multi-year agreement with Bayer Pharma AG, thereby extending an existing collaboration between the two companies.
Can Ohr Pharmaceutical (OHRP) Continue to Surge? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Mar 12, 7:52AM CDT
Ohr Pharmaceutical has seen its Zacks Rank surge over the past four weeks, moving from Sell territory to its current position as a Buy
Salix Pharmaceuticals Up 54.7% Since SmarTrend Uptrend Call (SLXP)
Comtex SmarTrend(R) - Tue Mar 11, 5:21PM CDT
SmarTrend identified an Uptrend for Salix Pharmaceuticals (NASDAQ:SLXP) on October 2nd, 2013 at $72.19. In approximately 5 months, Salix Pharmaceuticals has returned 54.74% as of today's recent price of $111.71.
New Diagnostic Test From Roche - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Mar 11, 10:30AM CDT
Roche recently announced that its new diagnostic test, Elecsys Syphilis immunoassay, is now available in the markets.
ArQule's Loss Narrows in Q4 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 06, 12:37PM CST
ArQule reported a loss of 10 cents per share in the fourth quarter of 2013, narrower than the Zacks Consensus Estimate of a loss of 13 cents per share.
Favorable Court Judgments, Stock Price Updates, and Upcoming Investors Conferences - Analyst Notes on Salix, Cerner, Hologic, Covance, and Synta
PR Newswire - Thu Mar 06, 8:20AM CST
Today, Analysts Review released its analysts' notes regarding Salix Pharmaceuticals Ltd. (NASDAQ: SLXP), Cerner Corporation (NASDAQ: CENR), Hologic Inc. (NASDAQ: HOLX), Covance Inc. (NYSE: CVD), and Synta Pharmaceuticals Corp. (NASDAQ: SNTA). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Top Mutual Funds Add To Health Care, Leisure And Banks
at Investor's Business Daily - Tue Mar 04, 5:20PM CST
After a volatile start in January, the stock market bounced back nicely in February with a good pop, helping to lift stock funds' recent purchases. The S&P 500 and the Dow each tacked on 4% during the Valentine month, while the biotech-heavy Nasdaq...
Salix Pharmaceuticals Shares Up 53.1% Since SmarTrend's Buy Recommendation (SLXP)
Comtex SmarTrend(R) - Tue Mar 04, 11:09AM CST
SmarTrend identified an Uptrend for Salix Pharmaceuticals (NASDAQ:SLXP) on October 2nd, 2013 at $72.19. In approximately 5 months, Salix Pharmaceuticals has returned 53.07% as of today's recent price of $110.50.
Salix Pharmaceuticals to Present at ROTH Conference
Business Wire - Tue Mar 04, 6:00AM CST
Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced that the Company will present at the 26th Annual ROTH Conference in Laguna Niguel, CA on Tuesday, March 11, 2014 at 1:30 p.m. PT (4:30 p.m. ET).
2 Weak Breakouts, A Few Sell-Offs For The IBD 50
at Investor's Business Daily - Fri Feb 28, 5:25PM CST
A couple of IBD 50 stocks broke out Friday, as the list of top-performing stocks also suffered at the hands of a few components that tumbled badly. The breakouts belonged to Signature Bank (SBNY) and Chipotle Mexican Grill (CMG). Chipotle saw a...
Stocks Hold Near Fresh Highs; 58.com Surges
at Investor's Business Daily - Fri Feb 28, 11:04AM CST
Stocks were holding near their session highs near Friday's midpoint. Overall, equities rallied in spite of a round of mixed economic data, including a downward revision to economic growth. The S&P 500 and the Nasdaq were up 0.5% and 0.2%,...
Stocks Buck Up In Early Trade; Salix, MercadoLibre On Fire
at Investor's Business Daily - Fri Feb 28, 9:37AM CST
Stocks pulled up from narrow early losses Friday after Midwest manufacturing and February consumer sentiment numbers topped expectations. All three major indexes, the Nasdaq, S&P 500 and the Dow Jones industrial average, were up 0.5% in early trade....
After Yesterday's Rally of 1.44% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Thu Feb 27, 5:38PM CST
Salix Pharmaceuticals (NASDAQ:SLXP) traded in a range yesterday that spanned from a low of $108.14 to a high of $111.26. Yesterday, the shares gained 1.4%, which took the trading range above the 3-day high of $110.93 on volume of 865,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Stocks End Higher; MercadoLibre Jumps After Hours
at Investor's Business Daily - Thu Feb 27, 3:58PM CST
Major averages closed higher Thursday after Federal Reserve chair Janet Yellen said bad weather may be behind recent weak economic data. The Nasdaq climbed 0.6%, while the Dow Jones industrial average and the S&P 500 added 0.5% each. But volume was...
Salix Pharmaceuticals Reports 4Q2013 and FY2013 Results
Business Wire - Thu Feb 27, 3:01PM CST
-- Full Year Product Revenue Increases 27% to $934 million
RedHill Biopharma and Salix Pharmaceuticals Announce Worldwide Exclusive License Agreement for RedHill's RHB-106 Encapsulated Bowel Preparation
GlobeNewswire - Thu Feb 27, 8:53AM CST
Salix Pharmaceuticals Ltd. (Nasdaq:SLXP) and RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL) today announced that they have entered into an exclusive agreement by which Salix has licensed the worldwide exclusive rights to RedHill's RHB-106 encapsulated formulation for bowel preparation and rights to other purgative developments.
Salix Pharmaceuticals and RedHill Biopharma Announce Worldwide Exclusive License Agreement for RedHill's RHB-106 Encapsulated Bowel Preparation
Business Wire - Thu Feb 27, 6:43AM CST
Salix Pharmaceuticals Ltd. (NASDAQ: SLXP) and RedHill Biopharma Ltd. (NASDAQ: RDHL; TASE: RDHL) today announced that they have entered into an exclusive agreement by which Salix has licensed the worldwide exclusive rights to RedHill's RHB-106 encapsulated formulation for bowel preparation and rights to other purgative developments.
Salix Wins Napo Pharmaceuticals Litigation
Business Wire - Tue Feb 25, 12:29PM CST
--Jury Finds Salix Did Not Breach License Agreement
Salix Pharmaceuticals Has Returned 49.5% Since SmarTrend Recommendation (SLXP)
Comtex SmarTrend(R) - Tue Feb 25, 10:03AM CST
SmarTrend identified an Uptrend for Salix Pharmaceuticals (NASDAQ:SLXP) on October 2nd, 2013 at $72.19. In approximately 5 months, Salix Pharmaceuticals has returned 49.54% as of today's recent price of $107.95.
Digia announces major update to Qt Enterprise Embedded out-of-the-box embedded software development offering
Business Wire - Tue Feb 25, 3:55AM CST
Embedded World -- Digia has released a major update to Qt Enterprise Embedded, the fully-integrated solution that enables users to get started immediately with software development for an embedded device with a tailored user experience. The Qt Enterprise Embedded update introduces several new value-add features that further increase developer efficiency, application and device performance and ultimately shortens software embedded development time to just hours.
Roche Collaborates with Bayer - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 12, 4:05PM CDT
Roche's Ventana Medical Systems, Inc. has entered into a multi-year agreement with Bayer Pharma AG, thereby extending an existing collaboration between the two companies.
Can Ohr Pharmaceutical (OHRP) Continue to Surge? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Mar 12, 7:52AM CDT
Ohr Pharmaceutical has seen its Zacks Rank surge over the past four weeks, moving from Sell territory to its current position as a Buy
Salix Pharmaceuticals Up 54.7% Since SmarTrend Uptrend Call (SLXP)
Comtex SmarTrend(R) - Tue Mar 11, 5:21PM CDT
SmarTrend identified an Uptrend for Salix Pharmaceuticals (NASDAQ:SLXP) on October 2nd, 2013 at $72.19. In approximately 5 months, Salix Pharmaceuticals has returned 54.74% as of today's recent price of $111.71.
New Diagnostic Test From Roche - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Mar 11, 10:30AM CDT
Roche recently announced that its new diagnostic test, Elecsys Syphilis immunoassay, is now available in the markets.
ArQule's Loss Narrows in Q4 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 06, 12:37PM CST
ArQule reported a loss of 10 cents per share in the fourth quarter of 2013, narrower than the Zacks Consensus Estimate of a loss of 13 cents per share.
Favorable Court Judgments, Stock Price Updates, and Upcoming Investors Conferences - Analyst Notes on Salix, Cerner, Hologic, Covance, and Synta
PR Newswire - Thu Mar 06, 8:20AM CST
Today, Analysts Review released its analysts' notes regarding Salix Pharmaceuticals Ltd. (NASDAQ: SLXP), Cerner Corporation (NASDAQ: CENR), Hologic Inc. (NASDAQ: HOLX), Covance Inc. (NYSE: CVD), and Synta Pharmaceuticals Corp. (NASDAQ: SNTA). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Top Mutual Funds Add To Health Care, Leisure And Banks
at Investor's Business Daily - Tue Mar 04, 5:20PM CST
After a volatile start in January, the stock market bounced back nicely in February with a good pop, helping to lift stock funds' recent purchases. The S&P 500 and the Dow each tacked on 4% during the Valentine month, while the biotech-heavy Nasdaq...
Salix Pharmaceuticals Shares Up 53.1% Since SmarTrend's Buy Recommendation (SLXP)
Comtex SmarTrend(R) - Tue Mar 04, 11:09AM CST
SmarTrend identified an Uptrend for Salix Pharmaceuticals (NASDAQ:SLXP) on October 2nd, 2013 at $72.19. In approximately 5 months, Salix Pharmaceuticals has returned 53.07% as of today's recent price of $110.50.
Salix Pharmaceuticals to Present at ROTH Conference
Business Wire - Tue Mar 04, 6:00AM CST
Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced that the Company will present at the 26th Annual ROTH Conference in Laguna Niguel, CA on Tuesday, March 11, 2014 at 1:30 p.m. PT (4:30 p.m. ET).
2 Weak Breakouts, A Few Sell-Offs For The IBD 50
at Investor's Business Daily - Fri Feb 28, 5:25PM CST
A couple of IBD 50 stocks broke out Friday, as the list of top-performing stocks also suffered at the hands of a few components that tumbled badly. The breakouts belonged to Signature Bank (SBNY) and Chipotle Mexican Grill (CMG). Chipotle saw a...
Stocks Hold Near Fresh Highs; 58.com Surges
at Investor's Business Daily - Fri Feb 28, 11:04AM CST
Stocks were holding near their session highs near Friday's midpoint. Overall, equities rallied in spite of a round of mixed economic data, including a downward revision to economic growth. The S&P 500 and the Nasdaq were up 0.5% and 0.2%,...
Stocks Buck Up In Early Trade; Salix, MercadoLibre On Fire
at Investor's Business Daily - Fri Feb 28, 9:37AM CST
Stocks pulled up from narrow early losses Friday after Midwest manufacturing and February consumer sentiment numbers topped expectations. All three major indexes, the Nasdaq, S&P 500 and the Dow Jones industrial average, were up 0.5% in early trade....
After Yesterday's Rally of 1.44% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Thu Feb 27, 5:38PM CST
Salix Pharmaceuticals (NASDAQ:SLXP) traded in a range yesterday that spanned from a low of $108.14 to a high of $111.26. Yesterday, the shares gained 1.4%, which took the trading range above the 3-day high of $110.93 on volume of 865,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Stocks End Higher; MercadoLibre Jumps After Hours
at Investor's Business Daily - Thu Feb 27, 3:58PM CST
Major averages closed higher Thursday after Federal Reserve chair Janet Yellen said bad weather may be behind recent weak economic data. The Nasdaq climbed 0.6%, while the Dow Jones industrial average and the S&P 500 added 0.5% each. But volume was...
Salix Pharmaceuticals Reports 4Q2013 and FY2013 Results
Business Wire - Thu Feb 27, 3:01PM CST
-- Full Year Product Revenue Increases 27% to $934 million
RedHill Biopharma and Salix Pharmaceuticals Announce Worldwide Exclusive License Agreement for RedHill's RHB-106 Encapsulated Bowel Preparation
GlobeNewswire - Thu Feb 27, 8:53AM CST
Salix Pharmaceuticals Ltd. (Nasdaq:SLXP) and RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL) today announced that they have entered into an exclusive agreement by which Salix has licensed the worldwide exclusive rights to RedHill's RHB-106 encapsulated formulation for bowel preparation and rights to other purgative developments.
Salix Pharmaceuticals and RedHill Biopharma Announce Worldwide Exclusive License Agreement for RedHill's RHB-106 Encapsulated Bowel Preparation
Business Wire - Thu Feb 27, 6:43AM CST
Salix Pharmaceuticals Ltd. (NASDAQ: SLXP) and RedHill Biopharma Ltd. (NASDAQ: RDHL; TASE: RDHL) today announced that they have entered into an exclusive agreement by which Salix has licensed the worldwide exclusive rights to RedHill's RHB-106 encapsulated formulation for bowel preparation and rights to other purgative developments.
Salix Wins Napo Pharmaceuticals Litigation
Business Wire - Tue Feb 25, 12:29PM CST
--Jury Finds Salix Did Not Breach License Agreement
Salix Pharmaceuticals Has Returned 49.5% Since SmarTrend Recommendation (SLXP)
Comtex SmarTrend(R) - Tue Feb 25, 10:03AM CST
SmarTrend identified an Uptrend for Salix Pharmaceuticals (NASDAQ:SLXP) on October 2nd, 2013 at $72.19. In approximately 5 months, Salix Pharmaceuticals has returned 49.54% as of today's recent price of $107.95.
Digia announces major update to Qt Enterprise Embedded out-of-the-box embedded software development offering
Business Wire - Tue Feb 25, 3:55AM CST
Embedded World -- Digia has released a major update to Qt Enterprise Embedded, the fully-integrated solution that enables users to get started immediately with software development for an embedded device with a tailored user experience. The Qt Enterprise Embedded update introduces several new value-add features that further increase developer efficiency, application and device performance and ultimately shortens software embedded development time to just hours.
(0)
(0)